Joseph W Kim MD

Assistant Professor of Medicine (Medical Oncology)

Specialties & Subspecialties

Cancer Center, Yale: Prostate and Urologic Cancers Program

Early Drug Development Program

Medical Oncology

Education & Training

  • M.D., Wake Forest University School of Medicine (2007)
  • Resident, Emory University School of Medicine , Internal Medicine (2007 - 2010)
  • Fellow, National Institutes of Health , National Cancer Institute and National Heart Lung and Blood Institute (2010 - 2013)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Prostate cancer, bladder cancer, immunotherapy, early drug development


Board Certifications

  • Hematology (Internal Medicine), Board Eligible
  • Medical Oncology, Board Certified (2013)
  • Internal Medicine, Board Certified (2010)

Clinical Trials

ConditionsStudy Title
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, and ThyroidA Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
ProstateSWOG S1216: A PHASE III RANDOMIZED TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY + TAK-700 WITH ANDROGEN DEPRIVATION THERAPY + BICALUTAMIDE IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Bladder, Breast - Female, Colon, Lung, Melanoma, skin, Other Endocrine System, Other Respiratory and Intrathoracic Organs, Other Urinary, Ovary, Rectum, and StomachA Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Breast - Female, Colon, Esophagus, Kidney, Liver, Lung, Melanoma, skin, Other Skin, and PancreasA Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors

More Clinical Trials...

Edit Profile